C WorldWide Group Holding A S Decreases Holdings in Insmed, Inc. (NASDAQ:INSM)

C WorldWide Group Holding A S trimmed its holdings in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 6.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 321,110 shares of the biopharmaceutical company's stock after selling 22,000 shares during the period. C WorldWide Group Holding A S owned 0.18% of Insmed worth $24,497,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of INSM. OneDigital Investment Advisors LLC increased its position in shares of Insmed by 47.1% during the first quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company's stock worth $399,000 after purchasing an additional 1,673 shares in the last quarter. Sowell Financial Services LLC acquired a new stake in shares of Insmed during the first quarter worth about $255,000. GAMMA Investing LLC increased its position in shares of Insmed by 62.0% during the first quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company's stock worth $77,000 after purchasing an additional 386 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Insmed by 16.7% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 3,772 shares of the biopharmaceutical company's stock worth $288,000 after purchasing an additional 541 shares in the last quarter. Finally, Envestnet Asset Management Inc. increased its position in shares of Insmed by 26.9% during the first quarter. Envestnet Asset Management Inc. now owns 325,307 shares of the biopharmaceutical company's stock worth $24,818,000 after purchasing an additional 68,949 shares in the last quarter.

Insider Buying and Selling at Insmed

In related news, insider Michael Alexander Smith sold 933 shares of the company's stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $102.51, for a total value of $95,641.83. Following the sale, the insider owned 66,394 shares of the company's stock, valued at approximately $6,806,048.94. This represents a 1.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Sara Bonstein sold 57,764 shares of the company's stock in a transaction that occurred on Monday, July 7th. The shares were sold at an average price of $95.86, for a total value of $5,537,257.04. Following the completion of the sale, the chief financial officer directly owned 84,017 shares in the company, valued at approximately $8,053,869.62. The trade was a 40.74% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 548,197 shares of company stock worth $49,124,834. Corporate insiders own 3.00% of the company's stock.

Insmed Price Performance

Shares of NASDAQ:INSM traded down $0.98 during trading on Friday, hitting $103.19. 100,372 shares of the stock were exchanged, compared to its average volume of 2,291,927. The company has a fifty day moving average price of $86.18 and a two-hundred day moving average price of $78.27. The company has a market cap of $19.58 billion, a PE ratio of -17.36 and a beta of 0.90. The company has a current ratio of 5.86, a quick ratio of 5.44 and a debt-to-equity ratio of 11.38. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $106.83.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing the consensus estimate of ($1.36) by ($0.06). The firm had revenue of $92.82 million for the quarter, compared to analysts' expectations of $91.63 million. Insmed had a negative return on equity of 446.98% and a negative net margin of 265.93%. Insmed's revenue was up 22.9% compared to the same quarter last year. During the same period last year, the firm earned ($1.06) EPS. On average, analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on INSM shares. Morgan Stanley boosted their price target on Insmed from $102.00 to $108.00 and gave the company an "overweight" rating in a research report on Thursday. Jefferies Financial Group restated a "buy" rating on shares of Insmed in a research report on Tuesday, June 10th. Wells Fargo & Company boosted their price target on Insmed from $107.00 to $119.00 and gave the company an "overweight" rating in a research report on Wednesday, June 11th. HC Wainwright boosted their price target on Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a research report on Wednesday, June 11th. Finally, Mizuho boosted their price target on Insmed from $96.00 to $110.00 and gave the company an "outperform" rating in a research report on Wednesday, June 11th. One research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $108.47.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.